Non Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12
This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery
25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small
cell lung cancer (NSCLC), i.e. 4 cycles of carboplatin-paclitaxel-bevacizumab, followed by
bevacizumab alone until disease progression. Tumor hypoxia is a common phenomenon in lung
cancer; it is a known poor prognostic marker, related to treatment resistance. Pre-clinical
studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia related drug
resistance. NTG is a NO donating drug. NTG increases tumor blood flow and thereby augments
antitumor drug delivery to the tumor.
A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG
patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with
advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.
The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab
containing chemotherapy improves progression free survival, response rate and overall
survival in patients with metastatic non-squamous NSCLC.
Standard treatment for non-small cell lung cancer (NSCLC) consists of platinum-containing
chemotherapy. It has been shown that the addition of bevacizumab to standard chemotherapy
improves progression-free survival (PFS) and overall survival (OS) in patients with
non-squamous NSCLC. There is a need for improved PFS and OS and response rates to
chemotherapy are only 25-35%.
Tumor hypoxia is a common phenomenon in lung cancer; it is a known poor prognostic marker,
related to treatment resistance. Hypoxia Inducible Factor (HIF) -1α is the major factor
regulating the response to hypoxia.
HIF directly activates vascular endothelial growth factor (VEGF) and VEGF-receptor.
Bevacizumab interacts with this pathway by blocking VEGF.
Pre-clinical studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia
related drug resistance. Nitroglycerin (NTG) is a NO donating drug. NTG increases tumor blood
flow and thereby augments antitumor drug delivery to the tumor and inhibits HIF-1α.
Interestingly, it has recently been shown in mouse models that the addition of HIF-1α
inhibitors to bevacizumab significantly inhibits tumor growth by inducing apoptosis.
A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG
patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with
advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.
The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab
containing chemotherapy improves PFS, response rate and OS in patients with metastatic
non-squamous NSCLC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |